New drug study aims to understand how liver disease affects medication
NCT ID NCT06825559
First seen Oct 31, 2025 · Last updated Jun 14, 2026 · Updated 34 times
Summary
This early-stage study will test a drug called saroglitazar magnesium in 6 adults with moderate liver scarring (cirrhosis) caused by cholestatic liver disease. The main goal is to see how the drug moves through the body and if it is safe when taken every other day. Participants will take the drug by mouth and have their blood tested regularly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLESTATIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zydus Site US001
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.